Aging Is Becoming a Drug Target. The Question Is Whether It’s a Disease
For most of modern medicine, aging has been treated as an inevitable backdrop to disease. Doctors treat cancer, diabetes, cardiovascular disease, and dementia, while the biological process that makes all of them more likely remains largely outside the boundaries of conventional treatment. That division is beginning to break down.
A growing pipeline of longevity drugs aims to intervene in aging itself, extending the years people spend healthy rather than targeting individual diseases one at a time. The scientific ambition is enormous. So are the implications for how medicine defines illness, approves treatments, and makes money.
